登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer
ClinicalTrials.gov 上登记的一项胰腺癌开放试验,由天津医科大学肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07436741,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Histologically or cytologically confirmed high-risk resectable or borderline resectable pancreatic cancer;
入选标准第 1 条
Have received blood transfusion treatment, blood products and hematopoietic factors, such as albumin and granulocyte colony-stimulating factor (G-CSF) within 14 days before enrollment;
排除标准第 2 条
Have received any surgery or invasive treatment or operation within 4 weeks before enrollment (except venous catheterization, puncture and drainage, etc.);
排除标准第 3 条
Eastern Cooperation Oncology Group (ECOG) performance status of 0-1;
入选标准第 5 条
At least one measurable lesion according to RECIST version 1.1;
入选标准第 7 条
Known human immunodeficiency virus (HIV) infection;
排除标准第 16 条
Women who are pregnant or lactating;
排除标准第 12 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07436741,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Histologically or cytologically confirmed high-risk resectable or borderline resectable pancreatic cancer; 18-75 years old (including 18 and 75 years old); No BRCA1/2 or PALB2 mutation; No previous pancreatic cancer resection, systemic therapy, or local radiation therapy; Eastern Cooperation Oncology Group (ECOG) performance status of 0-1; Life expectancy ≥ 6 months; At least one measurable lesion according to RECIST version 1.1; Adequate organ and bone marrow functions; Women of childbearing age need to take effective contraceptive measures.排除标准:Exclusion Criteria:
With distant metastasis; Have received blood transfusion treatment, blood products and hematopoietic factors, such as albumin and granulocyte colony-stimulating factor (G-CSF) within 14 days before enrollment; Have received any surgery or invasive treatment or operation within 4 weeks before enrollment (except venous catheterization, puncture and drainage, etc.); Allergic to the study drug or any of its adjuvants; Researchers judged clinically significant electrolyte abnormalities; History of serious cardiovascular and cerebrovascular diseases; With active ulcer, intestinal perforation and intestinal obstruction; Uncontrollable malignant ascites (defined as ascites that cannot be controlled by diuretics or puncture according to the judgment of the investigator); Clinically significant electrolyte abnormalities judged by researchers; With active bleeding or obvious evidence of bleeding tendency; Hypertension that cannot be controlled by drugs: systolic blood pressure ≥ 150 mmHg and / or diastolic blood pressure ≥ 100 mmHg; Women who are pregnant or lactating; Urinary protein ≥ ++, or the 24-hour urine protein quantification is greater than 1.0g; Concurrent tumors within 5 years (except treated cervical carcinoma in situ, basal cell carcinoma); Any disease or state that affects the absorption of drugs, or the subject cannot take oral drugs; Known human immunodeficiency virus (HIV) infection; History of clinically significant hepatic disease, including, but not limited to, known hepatitis B virus (HBV) infection with HBV DNA positive (copies ≥1×10\^4/ml or >2000 IU/ml); known hepatitis C virus infection with HCV RNA positive (copies ≥1×10\^3/m); hepatitis and cirrhosis; Have any other disease, metabolic disorder, physical examination anomaly, abnormal laboratory result, or any other conditions that makes the subject not suitable for enrolling according to the judgment of the investigator.
引自 ClinicalTrials.gov, NCT07436741, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07436741,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。